Last reviewed · How we verify
CT-P10
CT-P10 is a monoclonal antibody that binds to and inhibits TNF-alpha, reducing inflammatory signaling in autoimmune and inflammatory diseases.
CT-P10 is a monoclonal antibody that binds to and inhibits TNF-alpha, reducing inflammatory signaling in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | CT-P10 |
|---|---|
| Also known as | rituximab, Rituximab |
| Sponsor | Celltrion |
| Drug class | TNF-alpha inhibitor (monoclonal antibody / biosimilar) |
| Target | TNF-alpha (TNF-α) |
| Modality | Biologic |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
CT-P10 is a biosimilar of infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). By neutralizing TNF-α, a key pro-inflammatory cytokine, the drug suppresses the inflammatory cascade involved in autoimmune conditions. This mechanism allows immune tolerance to be restored in diseases driven by excessive TNF-α signaling.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Headache
- Infusion reactions
- Tuberculosis reactivation risk
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P10 CI brief — competitive landscape report
- CT-P10 updates RSS · CI watch RSS
- Celltrion portfolio CI